Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors

Biomaterials

Volumn 33, Issue 2, 2012, Pages 583-591

  Zhou, Jiangbing ^a,b   Patel, Toral R ^b   Fu, Michael ^a   Bertram, James P ^a   Saltzman, W Mark ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene delivery; Nanoparticle; PLGA; RNA interference

Indexed keywords

CELL PENETRATION; CLINICAL APPLICATION; FUNCTIONAL MODULES; GENE DELIVERY; GENE KNOCK DOWN; HUMAN USE; IN-VIVO; PLGA; PLGA NANOPARTICLES; RNA INTERFERENCE; SIRNA DELIVERY; TARGETED DELIVERY; TUMOR GROWTH; TUMOR TARGETING;

GENE THERAPY; GENE TRANSFER; RNA; TUMORS;

NANOPARTICLES;

NANOPARTICLE; POLYLACTIC ACID; POLYMER; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CELL CULTURE; DEGRADATION KINETICS; ENDOSOME; FEMALE; GENE SILENCING; HUMAN; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; RNA INTERFERENCE; SYNTHESIS; TUMOR GROWTH;

CELL LINE, TUMOR; CELL PROLIFERATION; ENDOSOMES; GENE KNOCKDOWN TECHNIQUES; GENE TRANSFER TECHNIQUES; HEK293 CELLS; HUMANS; LACTIC ACID; NANOPARTICLES; NEOPLASMS; POLYGLYCOLIC ACID; POLYMERS; RNA, SMALL INTERFERING;

EID: 80055103805     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.061     Document Type: Article

References (36)

1. Vaishnaw A.K., Gollob J., Gamba-Vitalo C., Hutabarat R., Sah D., Meyers R., et al. A status report on RNAi therapeutics. Silence 2010, 1:14.
2. Opko Health, Inc Safety and efficacy study evaluating the combination of Bevasiranib & Lucentis therapy in wet AMD (COBALT) 2011, Available from URL:, Online. http://clinicaltrials.gov/ct2/show/NCT00499590?term=bevasiranib%26rank=1.
3. Allergen, Inc A study using intravitreal injections of a small interfering RNA in patients with age-related macular degeneration 2011, Available from URL:, Online. http://clinicaltrials.gov/ct2/show/NCT00395057?term=macular%2Bdegeneration%2BsiRNA%26rank=1.
4. Pfizer, Inc Prospective, randomized, multi-center, comparator study evaluating efficacy and safety of PF-04523655 versus laser in subjects with diabetic macular edema (DEGAS) 2011, Available from URL:, Online. http://clinicaltrials.gov/ct2/show/NCT00701181?term=PF-04523655%26rank=1.
5. Tekmira Pharmaceuticals Corporation Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), of Liposomal siRNA in subjects with high cholesterol 2011, Available from URL:, Online. http://clinicaltrials.gov/ct2/show/NCT00927459?term=siRNA%26rank=10.
6. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
7. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005, 65:8984-8992.
8. Heidel J.D., Yu Z., Liu J.Y., Rele S.M., Liang Y., Zeidan R.K., et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A 2007, 104:5715-5721.
9. Chen Y., Bathula S.R., Yang Q., Huang L. Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol 2010, 130:2790-2798.
10. Pirollo K.F., Rait A., Zhou Q., Hwang S.H., Dagata J.A., Zon G., et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007, 67:2938-2943.
11. Shea L.D., Smiley E., Bonadio J., Mooney D.J. DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol 1999, 17:551-554.
12. Jones D.H., Corris S., McDonald S., Clegg J.C., Farrar G.H. Poly(dl-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997, 15:814-817.
13. Luo D., Woodrow-Mumford K., Belcheva N., Saltzman W.M. Controlled DNA delivery systems. Pharm Res 1999, 16:1300-1308.
14. Blum J.S., Saltzman W.M. High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-l-lysine. J Control Release 2008, 129:66-72.
15. Bertram J.P., Williams C.A., Robinson R., Segal S.S., Flynn N.T., Lavik E.B. Intravenous hemostat: nanotechnology to halt bleeding. Sci Transl Med 2009, 1:11ra22.
16. Fahmy T.M., Samstein R.M., Harness C.C., Mark Saltzman W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005, 26:5727-5736.
17. Cheng C.J., Saltzman W.M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 2011, 32:6194-6203.
18. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009, 16:510-520.
19. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
20. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
21. Lo S.L., Wang S. An endosomolytic tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 2008, 29:2408-2414.
22. Cheng J., Zeidan R., Mishra S., Liu A., Pun S.H., Kulkarni R.P., et al. Structure-function correlation of chloroquine and analogues as transgene expression enhancers in nonviral gene delivery. J Med Chem 2006, 49:6522-6531.
23. Bastos R., Pante N., Burke B. Nuclear pore complex proteins. Int Rev Cytol 1995, 162B:257-302.
24. Vandenbroucke R.E., Lucas B., Demeester J., De Smedt S.C., Sanders N.N. Nuclear accumulation of plasmid DNA can be enhanced by non-selective gating of the nuclear pore. Nucleic Acids Res 2007, 35:e86.
25. Shan G., Li Y., Zhang J., Li W., Szulwach K.E., Duan R., et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008, 26:933-940.
26. Judge A.D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009, 119:661-673.
27. Lavik E.B., Hrkach J.S., Lotan N., Nazarov R., Langer R. A simple synthetic route to the formation of a block copolymer of poly(lactic-co-glycolic acid) and polylysine for the fabrication of functionalized, degradable structures for biomedical applications. J Biomed Mater Res 2001, 58:291-294.
28. Steenblock E.R., Fahmy T.M. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther 2008, 16:765-772.
29. Tong C.L., Xiang G.H. Sensitive determination of enoxacin by its enhancement effect on the fluorescence of terbium(III)-sodium dodecylbenzene sulfonate and its luminescence mechanism. J Luminescence 2007, 126:575-580.
30. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006, 24:1005-1015.
31. Cu Y., LeMoellic C., Caplan M.J., Saltzman W.M. Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency. Nanomedicine 2010, 6:334-343.
32. Douglas K.L. Toward development of artificial viruses for gene therapy: a comparative evaluation of viral and non-viral transfection. Biotechnol Prog 2008, 24:871-883.
33. Li S.D., Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 2010, 145:178-181.
34. Achilefu S., Bloch S., Markiewicz M.A., Zhong T., Ye Y., Dorshow R.B., et al. Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. Proc Natl Acad Sci U S A 2005, 102:7976-7981.
35. Frankel P., Pellet-Many C., Lehtolainen P., D'Abaco G.M., Tickner M.L., Cheng L.L., et al. Chondroitin sulphate-modified neuropilin 1 is expressed in human tumour cells and modulates 3D invasion in the U87MG human glioblastoma cell line through a p130Cas-mediated pathway. Embo Rep 2008, 9:983-989.
36. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006, 6:321-330.